John Khadem is an Ophthalmology physician affiliated with New York Eye and Ear Infirmary. OpenAlex indexes 17 publications with 281 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20 W 13th St
New York, NY 100117995
Telephone
212-604-9800Provider last certified this registry record 7 Oct 2020.
Clinical trials
- Ozurdex for Macular Edema Post Membrane Peeling
Sponsor: Retina Specialists, PC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TOPCON HEALTHCARE, INC.Program year20252 payments
- Topcon Healthcare, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
54.8%Prostaglandin Analog12%Latanoprost75%Lumigan25%Part D≥60 patientsalpha-Adrenergic Agonist10.8%Brimonidine Tartrate45%Combigan33%Brimonidine Tartrate-Timolol17%Alphagan P5%Part D<11 patients+ 9 more classes in this area
Cancer & immunology
35.8%Vascular Endothelial Growth Factor Inhibitor31%Aflibercept85%Bevacizumab14%Eylea2%Part D + Part B<11 patientsCalcineurin inhibitor4.8%Restasis78%Cyclosporine22%Part D<11 patientsCardiovascular
4.4%Beta blocker4.4%Timolol Maleate100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of Ozurdex on Persistent Macular Edema After Vitrectomy with Membrane Peeling
Investigative Ophthalmology & Visual Science
2013 - The Effects Of Epiretinal Membrane Peeling Procedure On Transverse Macular Expansion And Mechanical Aniseikonia
Investigative Ophthalmology & Visual Science
2012 - Prevalence of Retinal Pigment Epithelial Tear Following Intravitreal Ranibizumab Injection for Exudative Macular Degeneration
Investigative Ophthalmology & Visual Science
2007 - Healing of perforating rat corneal incisions closed with photodynamic laser‐activated tissue glue
Lasers in Surgery and Medicine
2004
Similar KOLs
Other experts from the same institution or the same specialty.
Janet Serle, MD
New York Eye and Ear Infirmary
Gennady Landa, MD
New York Eye and Ear Infirmary
Kateki Vinod, MD
New York Eye and Ear Infirmary
Rudrani Banik, MD
New York Eye and Ear Infirmary
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”